Viridian Therapeutics Files 8-K

Ticker: VRDN · Form: 8-K · Filed: May 20, 2025 · CIK: 1590750

Sentiment: neutral

Topics: corporate-filing, regulation-fd, financials

TL;DR

Viridian Therapeutics filed an 8-K on 5/20/25, check for financial updates.

AI Summary

Viridian Therapeutics, Inc. filed an 8-K on May 20, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc., is incorporated in Delaware and headquartered in Waltham, MA.

Why It Matters

This filing indicates routine corporate reporting, including financial updates and exhibits, which are important for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This is a standard 8-K filing for corporate reporting and does not appear to contain any immediately alarming information.

Key Numbers

Key Players & Entities

FAQ

What specific financial statements or exhibits are included in this 8-K filing?

The filing explicitly states 'Financial Statements and Exhibits' as an item information, but the specific details of these documents are not provided in the provided text.

What is the significance of the 'Regulation FD Disclosure' item?

Regulation FD (Fair Disclosure) ensures that material non-public information is disclosed to all investors simultaneously, preventing selective disclosure.

When was Viridian Therapeutics, Inc. previously known as Miragen Therapeutics, Inc. or Signal Genetics, Inc.?

The company was formerly known as Miragen Therapeutics, Inc. with a name change date of 20170213, and prior to that, Signal Genetics, Inc. with a name change date of 20140710.

What is the primary business of Viridian Therapeutics, Inc. based on its SIC code?

The Standard Industrial Classification (SIC) code 2834 indicates that the company is in the business of 'Pharmaceutical Preparations'.

What is the physical address of Viridian Therapeutics, Inc.'s headquarters?

The company's business address is listed as 221 Crescent Street, Suite 103A, Waltham, MA 02453.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 20, 2025 regarding Viridian Therapeutics, Inc.\DE (VRDN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing